Results 71 to 80 of about 21,291 (219)

Interleukin-33 and Mast Cells Bridge Innate and Adaptive Immunity: From the Allergologist’s Perspective [PDF]

International Neurourology Journal, 2015
Interleukin (IL) 33, a member of the IL-1 superfamily, is an “alarmin” protein and is secreted in its active form from damaged cells undergoing necrotic cell death. Mast cells are one of the main effector cell types in allergic disorders.
Tae Young Jang, Young Hyo Kim
doaj   +1 more source

Investigations of urethral sphincter activity in mice with bladder hyperalgesia before and after drug administration of gabapentin. [PDF]

, 2019
PurposeThis study investigated the effect of gabapentin on lower urinary tract dysfunction focusing on urethral activities and cystitis-induced hyperalgesia in a mouse model of painful bladder syndrome/interstitial cystitis (PBS/IC). The electromyography&
Chang, Huiyi H, Chen, Jia-Jin, Choi, Hanul, Do, Rebecca, Ghoniem, Gamal, Lin, Ching-Ting, Yeh, Jih-Chao, Zi, Xiaolin   +7 more
core  

Intravesical therapy for recurrent urinary tract infection: a systematic review and meta‐analysis

BJU International, EarlyView.
Objective To undertake a systematic review and meta‐analysis to evaluate the efficacy, safety, and clinical applicability of intravesical instillations for preventing recurrent urinary tract infections (rUTIs). Methods PubMed/MEDLINE, Embase, Cochrane CENTRAL, Scopus, and Web of Science were searched from January 2000 to April 2025 for randomised and ...
Matthew Kwon, Asaad Ahmad, Natalie Lott, Alison Blatt   +3 more
wiley   +1 more source

Successful treatment of eosinophilic cystitis with benralizumab

Urology Case Reports, 2020
Eosinophilic cystitis is a rare form of interstitial cystitis. It can be chronic and debilitating due to urinary frequency, dysuria, incontinence, and frequent urinary tract infections.
W Donald Cooke, Abigail J Tarr Cooke
doaj   +1 more source

Diagnosis in a Preclinical Model of Bladder Pain Syndrome Using a Au/ZnO Nanorod-based SERS Substrate [PDF]

, 2019
To evaluate the feasibility of ZnO nanorod-based surface enhanced Raman scattering (SERS) diagnostics for disease models, particularly for interstitial cystitis/bladder pain syndrome (IC/BPS), ZnO-based SERS sensing chips were developed and applied to an
Choo, Myung-Soo, Jeon, Sangmin, Joo, Jinmyoung, Jue, Miyeon, Kim, Gwanho, Kim, Jun Ki, Lee, Sanghwa, Namgoong, Jung-Man, Pack, Chan-Gi, Shin, Dong-Myung, Yu, Hwan Yeul   +10 more
core   +1 more source

Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders

British Journal of Pharmacology, EarlyView.
Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman, Christopher J. Black, Andrea Shin, Daniel Keszthelyi   +3 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

D-mannose: a promising support for acute urinary tract infections in women. A pilot study [PDF]

, 2016
Urinary tract infections still represent a significant bother for women and result in high costs to the health system. D-mannose is a simple sugar; it seems able to hinder bacteria adhesion to the urothelium.
BENEDETTI PANICI, PIERLUIGI, BRACCHI, CARLOTTA, COLAGIOVANNI, VANESSA, DOMENICI, LAVINIA, GIORGINI, MARGHERITA, MONTI, Marco, MUZII, LUDOVICO   +6 more
core  

Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: A pilot study [PDF]

, 2006
Objective: We evaluated the efficacy and tolerability of botulinum A toxin (BTX-A) intravesical injections in patients affected by painful bladder syndrome with increased urinary frequency, refractory to conventional treatment modalities. Methods: Twelve
Bini, V, Costantini, E, Di Stasi, SM, Giannantoni, A, Porena, M., Tascini, MC   +5 more
core   +2 more sources

Downstream Treatment Burden and Health‐Care Utilization Following Initiation of GLP‐1 Receptor Agonists or SGLT2 Inhibitors in Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and sodium–glucose cotransporter 2 (SGLT2) inhibitors are widely used for the treatment of type 2 diabetes, yet their downstream consequences in routine clinical practice remain incompletely characterized.
Yazan Alhamdan, Jason C. Hsu, Christine Y. Lu   +2 more
wiley   +1 more source